Claims:

1. Use of an antibody having the ability of binding to CLDN18.2 for the preparation of a medicament for ~~A method of~~ treating or preventing a cancer disease ~~comprising administering to a patient an antibody having the ability of binding to CLDN18.2~~ in a combination therapy with an agent stimulating γδ T cells, wherein the agent stimulating γδ T cells is a bisphosphonate and wherein said agent is for administration to ~~the~~a patient in a combination therapy with interleukin-2.

2. The ~~method~~ use of claim 1, wherein the γδ T cells are Vγ9Vδ2 T cells.

~~3. The method of claim 1 or 2, wherein the agent stimulating γδ T cells is a bisphosphonate.~~

~~4~~3. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 ~~to 3~~or 2, wherein the agent stimulating γδ T cells is a nitrogen-containing bisphosphonate (aminobisphosphonate).

~~5~~4. The ~~method~~ use of any one of claims 1 to ~~4~~3, wherein the agent stimulating γδ T cells is selected from the group consisting of zoledronic acid, clodronic acid, ibandronic acid, pamidronic acid, risedronic acid, minodronic acid, olpadronic acid, alendronic acid, incadronic acid and salts thereof.

~~6. The method of any one of claims 1 to 5, wherein the agent stimulating γδ T cells is administered in combination with interleukin-2.~~

~~7~~5. The ~~method~~ use of any one of claims 1 to ~~6~~4, wherein the ~~method~~ combination therapy further comprises ~~administering~~ an agent stabilizing or increasing expression of CLDN18.2, wherein the agent stabilizing or increasing expression of CLDN18.2 is selected from the group consisting of (i) oxaliplatin and 5-fluorouracil, (ii) epirubicin, oxaliplatin and 5-fluorouracil; (iii) 5-fluorouracil, folinic acid and oxaliplatin, (iv) Irinotecan, (v) Docetaxel and (vi) Cisplatin and prodrugs thereof.

~~8~~6. The ~~method~~ use of claim ~~7~~5, wherein expression of CLDN18.2 is at the cell surface of a cancer cell.

~~9. The method of claim 7 or 8, wherein the agent stabilizing or increasing expression of CLDN18.2 comprises an agent which induces a cell cycle arrest or an accumulation of cells in one or more phases of the cell cycle, preferably in one or more phases of the cell cycle other than the G1 phase, more preferably in the G2 phase and/or the S phase.~~

~~10. The method of any one of claims 7 to 9, wherein the agent stabilizing or increasing expression of CLDN18.2 comprises an agent selected from the group consisting of anthracyclines, platinum compounds, nucleoside analogs, taxanes, and camptothecin analogs, or prodrugs thereof, and combinations thereof.~~

~~11. The method of any one of claims 7 to 10, wherein the agent stabilizing or increasing expression of CLDN18.2 comprises an agent selected from the group consisting of epirubicin, oxaliplatin, cisplatin, 5-fluorouracil or prodrugs thereof, docetaxel, irinotecan, and combinations thereof.~~

~~12. The method of any one of claims 7 to 11, wherein the agent stabilizing or increasing expression of CLDN18.2 comprises a combination of oxaliplatin and 5-fluorouracil or prodrugs thereof, a combination of cisplatin and 5-fluorouracil or prodrugs thereof, a combination of at least one anthracycline and oxaliplatin, a combination of at least one anthracycline and cisplatin, a combination of at least one anthracycline and 5-fluorouracil or prodrugs thereof, a combination of at least one taxane and oxaliplatin, a combination of at least one taxane and cisplatin, a combination of at least one taxane and 5-fluorouracil or prodrugs thereof, or a combination of at least one camptothecin analog and 5-fluorouracil or prodrugs thereof.~~

~~13. The method of any one of claims 7 to 12, wherein the agent stabilizing or increasing expression of CLDN18.2 is an agent inducing immunogenic cell death.~~

~~14. The method of claim 13, wherein the agent inducing immunogenic cell death comprises an agent selected from the group consisting of anthracyclines, oxaliplatin and combinations thereof.~~

~~15. The method of any one of claims 7 to 14, wherein the agent stabilizing or increasing expression of CLDN18.2 comprises a combination of epirubicin and oxaliplatin.~~

~~16. The method of any one of claims 7 to 15, wherein the method comprises administering at least one anthracycline, at least one platinum compound and at least one of 5-fluorouracil and prodrugs thereof.~~

~~17. The method of any one of claims 10 to 16, wherein the anthracycline is selected from the group consisting of epirubicin, doxorubicin, daunorubicin, idarubicin and valrubicin, and preferably is epirubicin.~~

~~18. The method of any one of claims 10 to 17, wherein the platinum compound is selected from the group consisting of oxaliplatin and cisplatin.~~

~~19. The method of any one of claims 10 to 18, wherein the nucleoside analog is selected from the group consisting of 5-fluorouracil and prodrugs thereof.~~

~~20. The method of any one of claims 10 to 19, wherein the taxane is selected from the group consisting of docetaxel and paclitaxel.~~

~~21. The method of any one of claims 10 to 20, wherein the camptothecin analog is selected from the group consisting of irinotecan and topotecan.~~

~~22. The method of any one of claims 7 to 21, wherein the method comprises administering (i) epirubicin, oxaliplatin and 5-fluorouracil, (ii) epirubicin, oxaliplatin and capecitabine, (iii) epirubicin, cisplatin and 5-fluorouracil, (iv) epirubicin, cisplatin and capecitabine, or (v) folinic acid, oxaliplatin and 5-fluorouracil.~~

~~23~~7. The ~~method~~ use of any one of claims 1 to ~~22~~6, wherein the antibody having the ability of binding to CLDN18.2 binds to the first extracellular loop of CLDN18.2.

~~24~~8. The ~~method~~ use of any one of claims 1 to ~~23~~7, wherein the antibody having the ability of binding to CLDN18.2 mediates cell killing by one or more of complement dependent cytotoxicity (CDC) mediated lysis, antibody dependent cellular cytotoxicity (ADCC) mediated lysis, induction of apoptosis and inhibition of proliferation.

~~25~~9. The ~~method~~ use of any one of claims 1 to ~~24~~8, wherein the antibody having the ability of binding to CLDN18.2 is an antibody selected from the group consisting of (i) an antibody produced by and/or obtainable from a clone deposited under the accession no. DSM ACC2737, DSM ACC2738, DSM ACC2739, DSM ACC2740, DSM ACC2741, DSM ACC2742, DSM ACC2743, DSM ACC2745, DSM ACC2746, DSM ACC2747, DSM ACC2748, DSM ACC2808, DSM ACC2809, or DSM ACC2810, (ii) an antibody which is a chimerized or humanized form of the antibody under (i), (iii) an antibody having the specificity of the antibody under (i) and (iv) an antibody comprising the antigen binding portion or antigen binding site, in particular the variable region, of the antibody under (i) and preferably having the specificity of the antibody under (i).

~~26~~10. The ~~method~~ use of any one of claims 1 to ~~25~~9, wherein ~~the method comprises administering~~ the antibody having the ability of binding to CLDN18.2 is for administration at a dose of up to 1000 mg/m^2.

~~27~~11. The ~~method~~ use of any one of claims 1 to ~~26~~10, wherein ~~the method comprises administering~~ the antibody having the ability of binding to CLDN18.2 is for administration repeatedly at a dose of 300 to 600 mg/m^2.

~~28~~12. The ~~method~~ use of any one of claims 1 to ~~27~~11, wherein the cancer is CLDN18.2 positive.

~~29~~13. The ~~method~~ use of any one of claims 1 to ~~28~~12, wherein the cancer is an adeno-carcinoma, in particular an advanced adenocarcinoma.

~~30~~14. The ~~method~~ use of any one of claims 1 to ~~29~~13, wherein the cancer is selected from the group consisting of cancer of the stomach, cancer of the esophagus, in particular the lower esophagus, cancer of the eso-gastric junction and gastroesophageal cancer.

~~31~~15. The ~~method~~ use of any one of claims 1 to ~~30~~14, wherein the patient is a HER2/neu negative patient or a patient with HER2/neu positive status but not eligible to trastuzumab therapy.

~~32~~16. The ~~method~~ use of any one of claims 1 to ~~31~~15, wherein CLDN18.2 has the amino acid sequence according to SEQ ID NO: 1.

~~33~~17. A medical preparation comprising an antibody having the ability of binding to CLDN18.2 and an agent stimulating γδ T cells, wherein the agent stimulating γδ T cells is a bisphosphonate.

~~34~~18. The medical preparation of claim ~~33~~17, which further comprises an agent stabilizing or increasing expression of CLDN18.2, wherein the agent stabilizing or increasing expression of CLDN18.2 is selected from the group consisting of (i) oxaliplatin and 5-fluorouracil, (ii) epirubicin, oxaliplatin and 5-fluorouracil; (iii) 5-fluorouracil, folinic acid and oxaliplatin, (iv) Irinotecan, (v) Docetaxel and (vi) Cisplatin and prodrugs thereof.

~~35~~19. The medical preparation of claim ~~33~~ 17 or ~~34~~18, which is a kit comprising a first container including the antibody having the ability of binding to CLDN18.2 and a container including the agent stimulating γδ T cells, and optionally and a container including the agent stabilizing or increasing expression of CLDN18.2.

~~36~~20. The medical preparation of any one of claims ~~33~~ 17 to ~~35~~19, further including printed instructions for use of the preparation for treatment of cancer.